Oxygen Therapy in Patients With Chronic Heart Failure With Reduced Ejection Fraction (ROXIC)
Chronic Heart Failure, Oxygen Deficiency
About this trial
This is an interventional treatment trial for Chronic Heart Failure focused on measuring oxygen therapy
Eligibility Criteria
Inclusion Criteria: Patients > 18 years old. Diagnosis and clinic of chronic heart failure with ventricular dysfunction with left ventricular ejection fraction (LVEF) <40% under optimal medical treatment regardless of its etiology and having presented at least one episode of decompensation (visits to the emergency room, hospitalizations and/or need for intravenous depletive treatment) during the last year. Nocturnal desaturation defined as mean SatO2 <90% and/or Cummulative time (TC) <90>22 minutes to nocturnal pulse oximetry done at home. Signed informed consent Exclusion Criteria: Chronic lung disease (includes chronic obstructive pulmonary disease with Pulmonary respiratory function (PRF) (forced expiratory volume at one second/forced vital capacity (FEV1/FVC) <70%), diffuse interstitial diseases, pulmonary hypertension of respiratory). Obstructive sleep apnea-hypopnea syndrome (OSAHS) with Apnea hypopnea index (AHI) > 14.9. Previous treatment with oxygen therapy. Not agreeing to attend periodic cardiology visits. Being part of other clinical studies that contraindicate an intervention. Pregnant or breastfeeding women.
Sites / Locations
- University Hospital of Girona Dr. Josep TruetaRecruiting
Arms of the Study
Arm 1
Arm 2
Active Comparator
No Intervention
Oxygen Therapy
No Oxygen Therapy
Participants received nocturnal oxygen therapy (minimum 6 hours) for 6 months.
Participants will not received oxygen therapy